Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
New England Journal of Medicine2022Vol. 386(10), pp. 951–963
Citations Over TimeTop 1% of 2022 papers
Roos S. G. Sablerolles, Wim J. R. Rietdijk, Abraham Goorhuis, Douwe F. Postma, Leo G. Visser, Daryl Geers, Katharina S. Schmitz, Hannah M. Garcia Garrido, Marion Koopmans, Virgil A. S. H. Dalm, Neeltje A. Kootstra, Anke Huckriede, Melvin Lafeber, Debbie van Baarle, Corine H. GeurtsvanKessel, Rory D. de Vries, P.H.M. van der Kuy
Abstract
The Ad26.COV2.S and mRNA boosters had an acceptable safety profile and were immunogenic in health care workers who had received a priming dose of Ad26.COV2.S vaccine. The strongest responses occurred after boosting with mRNA-based vaccines. Boosting with any available vaccine was better than not boosting. (Funded by the Netherlands Organization for Health Research and Development ZonMw; SWITCH ClinicalTrials.gov number, NCT04927936.).
Related Papers
- → Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1–11-year-old children(2005)19 cited
- → Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme(2021)7 cited
- → Comparison of the reactogenicity and immunogenicity of two different dose levels of inactivated hepatitis a vaccine in healthy children and adolescents(1998)
- → Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60–85 years in a randomized, double-blind, phase 1 study(2024)